GT Biopharma (NASDAQ:GTBP – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($1.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.50) by $0.52, reports.
GT Biopharma Stock Performance
Shares of NASDAQ:GTBP traded up $0.24 on Wednesday, hitting $3.42. 26,556 shares of the company were exchanged, compared to its average volume of 55,270. The company’s 50 day moving average price is $6.10 and its two-hundred day moving average price is $9.01. The firm has a market capitalization of $7.06 million, a price-to-earnings ratio of -0.02 and a beta of 0.88. GT Biopharma has a one year low of $3.10 and a one year high of $23.60.
Analyst Upgrades and Downgrades
GTBP has been the topic of a number of recent analyst reports. Wall Street Zen downgraded GT Biopharma to a “strong sell” rating in a research note on Saturday, September 12th. Weiss Ratings restated a “sell (e+)” rating on shares of GT Biopharma in a report on Friday, October 2nd. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has an average rating of “Sell”.
Read Our Latest Stock Analysis on GT Biopharma
GT Biopharma Company Profile
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research centers on its TriKE platform, which is designed to direct natural killer (NK) cells toward cancer cells and support their activity using an immune-stimulating signal. The company’s pipeline includes GTB-3650, a candidate designed to target CD33-expressing blood cancers such as acute myeloid leukemia, and GTB-5550, a candidate targeting B7-H3, a protein found on various solid tumors.
Read More
- Five stocks we like better than GT Biopharma
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
